This site is intended for health professionals only

Circadin ®▼ – Information from Lundbeck Ltd

03 September 2012

Circadin ® (prolonged release melatonin) licence extended to include treatment for up to 13 weeks¹ in patients with primary insomnia

Dialogue with elderly patients

Prescribing information

The role of melatonin in sleep

The role of prolonged-release melatonin in the management of primary insomnia

Related Articles

CPD: Managing patients with medically unexplained symptoms – beyond investigations

07 March 2025

AstraZeneca takes ‘commercial decision’ to withdraw Covid vaccine

10 May 2024

Overdiagnosis: The diagnostic challenges in long Covid

21 March 2024